Adiponectin
Adiponectin is a protein hormone that is involved in regulating glucose levels as well as fatty acid breakdown. It is encoded by the ADIPOQ gene in humans. Adiponectin is produced and secreted by adipose tissue (fat cells) and is found in the bloodstream. It plays a crucial role in various metabolic processes, including glucose regulation and fatty acid oxidation.
Structure and Function[edit | edit source]
Adiponectin is a 244-amino acid protein that circulates in the blood in relatively high concentrations. It exists in multiple forms, including low-molecular-weight trimers, medium-molecular-weight hexamers, and high-molecular-weight multimers. The high-molecular-weight form is believed to be the most biologically active.
Adiponectin enhances the body's sensitivity to insulin, making it a key player in the management of type 2 diabetes. It also has anti-inflammatory properties and is involved in the suppression of metabolic derangements that may result in obesity, type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD).
Mechanism of Action[edit | edit source]
Adiponectin exerts its effects by binding to specific receptors, known as adiponectin receptors (AdipoR1 and AdipoR2), which are widely distributed in various tissues, including the liver, skeletal muscle, and endothelial cells. Upon binding to these receptors, adiponectin activates several intracellular signaling pathways, including the AMP-activated protein kinase (AMPK) pathway and the peroxisome proliferator-activated receptor alpha (PPAR-α) pathway. These pathways play a significant role in enhancing insulin sensitivity and promoting fatty acid oxidation.
Clinical Significance[edit | edit source]
Low levels of adiponectin are associated with several metabolic disorders, including obesity, type 2 diabetes, cardiovascular disease, and metabolic syndrome. Conversely, higher levels of adiponectin are generally associated with a reduced risk of these conditions. Therefore, adiponectin is considered a potential therapeutic target for the treatment of metabolic diseases.
Research and Therapeutic Potential[edit | edit source]
Research is ongoing to develop therapies that can increase adiponectin levels or mimic its action. Such therapies could potentially be used to treat conditions like type 2 diabetes, obesity, and cardiovascular disease. Additionally, lifestyle interventions such as diet and exercise have been shown to increase adiponectin levels, thereby improving metabolic health.
See Also[edit | edit source]
- Adipose tissue
- Insulin resistance
- Type 2 diabetes
- Metabolic syndrome
- Cardiovascular disease
- Non-alcoholic fatty liver disease
- AMP-activated protein kinase
- Peroxisome proliferator-activated receptor alpha
References[edit | edit source]
External Links[edit | edit source]
This hormone-related article is a stub. You can help WikiMD by expanding it.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD